How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy
Journal of Cellular Physiology
Published online on June 02, 2016
Abstract
Chimeric antigen receptor (CAR) T cells have been developed to treat tumors and have shown great success against B cell malignancies. Exploiting modular designs and swappable domains, CARs can target an array of cell surface antigens and, upon receptor‐ligand interactions, direct signaling cascades, thereby driving T cell effector functions. CARs have been designed using receptors, ligands, or scFv binding domains. Different regions of a CAR have each been found to play a role in determining the overall efficacy of CAR T cells. Therefore, this review provides an overview of CAR construction and common designs. Each CAR region is discussed in the context of its importance to a CAR's function. Additionally, the review explores how various engineering strategies have been applied to CAR T cells in order to regulate CAR T cell function and activity. J. Cell. Physiol. 231: 2590–2598, 2016. © 2016 Wiley Periodicals, Inc.
Chimeric antigen receptor (CAR) T cells are able to eliminate late stage hematological cancers and have a great potential to treat many types of cancer. This review summarizes how the design of CARs alters their function and T cell responses.